Análisis Argos
ILMN
ILMNCara
Illumina, Inc. · Healthcare
US$ 188.68
precio al 2026-07-04
Valor justo Argos*
US$ 127
vs. su valor justo
▼−33%
Score Argos
49/100
LA RESPUESTA
El mercado le pide crezca 54.3% al año — más de lo que ha demostrado (9.3%). Estás pagando un futuro que todavía no probó: el margen de error es mínimo.
Recompensas
✓Retorno sobre el capital alto (18%).
Riesgos
!El precio pide más crecimiento del que la empresa ha demostrado.
!Venta significativa de insiders en el último trimestre.
VALOR1/6FUTURO3/6PASADO4/6SALUD3/6DIVIDENDO3/6
El Iris de calidad
VALOR1/6FUTURO3/6PASADO4/6SALUD3/6DIVIDENDO3/6
ValorCotiza por encima de su valor justo
FuturoCrecimiento moderado
PasadoFundamentales sólidos y sostenidos
SaludBalance razonable
DividendoRetorno al accionista moderado
Score Argos49de 100Cara
Ingresos▼1%
US$ 4.3 B
Margen operativo▼204%
19.9%
Flujo de caja libre▲31%
US$ 0.9 B
Deuda neta
US$ 1.1 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 28.5B
P/E33.6x
EV/EBITDA26.2x
FCF yield3.3%
ROIC17.5%
Margen operativo19.9%
Crecim. ingresos-0.8%/año
Piotroski F8/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

prnewswire.com · 23 jun
Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors
Eli Lilly and Company's Chief Scientific and Product Officer brings pharmaceutical R&D and scientific leadership perspective to Illumina's Board SAN DIEGO, June 23, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the appointment of Daniel M. Skovronsky, MD, PhD, to its Board of Directors, effective June 16, 2026.
forbes.com · 17 jun
The Healthcare M&A Wave
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
zacks.com · 17 jun
Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
zacks.com · 11 jun
Why Illumina (ILMN) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
fxempire.com · 9 jun
Illumina (ILMN): Bullish Structure Builds After Breakout
Illumina maintains a long-term bullish reversal after breaking out of an inverse head and shoulders pattern, with key support holding as upside targets remain in focus.
prnewswire.com · 8 jun
Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution
StrataMap Spatial gives researchers access to spatial biology at true single cell resolution for discovery without boundaries Whole-transcriptome profiling across a large tissue capture area can generate 2x more unique genes per sample than probe-based technologies SAN DIEGO, June 8, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the launch of the StrataMap Spatial Solution, offering an unmatched breadth of coverage and resolution to redefine what researchers can detect with spatial transcriptomics. StrataMap Spatial, previously called the Illumina Spatial Solution, is an end-to-end sequencing-based research solution to uncover spatial insights.
investorplace.com · 5 jun
Skip the Oura Ring IPO. Buy These 10 Stocks Instead.
Oura Ring's IPO looks like Peloton in 2020 - great product, dangerous price. Ten public wellness stocks own the real trade.
fool.com · 4 jun
Is Grail Stock a Bad-News Buy After Its Recent Pullback?
The cancer test maker could still have a bright future.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.